A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 559 participants.

Also called NCT05971940

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 559 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05971940
Other papers using this trial's data
  • Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes The New England journal of medicine, 2025-09-18 DOI, PubMed 40544435

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, China, India, Japan, Mexico, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05971940. Randomized; double masking; primary purpose treatment. Start 2023-08-09 (actual); primary completion 2025-04-03 (actual). Results posted on 2026-04-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Acronym
ACHIEVE-1
Intervention (Drug)
Orforglipron
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05971940
Content hash
e113b25c29fa6f990b1ecc1d8d86e02a0af4cfc9051efab6b60154da354bd25b